Cancer

Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development

EXTON, Pa., Jan. 30, 2026 /PRNewswire/ -- Frontage Laboratories, Inc. ("Frontage"), a global Contract Research, Development and Manufacturing Organization (CRDMO),…

2 weeks ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the…

2 weeks ago

Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing…

2 weeks ago

ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage…

2 weeks ago

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”),…

2 weeks ago

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed…

2 weeks ago

IO Biotech Provides Corporate Update

Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

2 weeks ago

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and…

2 weeks ago

Yunu Extends from Site Imaging Standard to Central Review Workflow Leader

New Imaging Automation Delivers a Modern Framework for Central Review & Site Collaboration CARY, NORTH CAROLINA / ACCESS Newswire /…

2 weeks ago

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series…

2 weeks ago